EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial

Maurizio Vecchi, Gian Eugenio Tontini, Giancarla Fiori, Paolo Bocus, Marino Carnovali, Paola Cesaro, Guido Costamagna, Dhanai Di Paolo, Luca Elli, Olga Fedorishina, Carsten Hinkel, Ralf Jakobs und 15 weitere

Digestive and Liver Disease · 2025-02 · 57 (2) · 574-583

DOI: 10.1016/j.dld.2024.09.024 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Digestive and Liver Disease, 2025-02. Verfasst von Maurizio Vecchi und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology and Organ Transplantation, University of Milan, Milan, Italy; IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation…. Hauptthemen laut MEDLINE: Cathartics, Colonoscopy, Mannitol, Patient Satisfaction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Transportation Center, Morgan State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bowel preparation represents a significant issue to high-quality colonoscopy. Oral mannitol requires a single dose, is of low volume, and has a pleasant taste and rapid action. AIMS: This SATISFACTION study compared single-dose (same day) oral mannitol 100 g/750 mL with standard split-dose PEG-ASC2 L (MoviPrep®). METHODS: The primary endpoint was the proportion of patients with adequate bowel cleansing. Secondary endpoints included efficacy (adenoma detection rate, caecal intubation rate, time of evacuation), safety (intestinal gases concentration, haemato-chemical parameters, adverse events), and patient satisfaction. RESULTS: The study included 703 patients (352 treated with mannitol and 351 with PEG-ASC). Mannitol was not inferior to PEG-ASC for the primary endpoint (91.1 % and 95.5 %, respectively; p-value for the non-inferiority =0.0131). There was no significant difference for secondary efficacy endpoints. The acceptability profile was significantly better in the mannitol group for ease of use, taste, and willingness to reuse (p < 0.0001 for all). The concentration of intestinal gases (H2, CH4) was similar between groups and well below those potentially critical. CONCLUSIONS: The SATISFACTION study indicated that low-volume, single-dose mannitol may satisfy an unmet clinical need since it was more acceptable to the patient and not inferior to the split-dose PEG-ASC for bowel cleansing efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CatharticsColonoscopyMannitolPatient SatisfactionPolyethylene GlycolsAdultAgedFemaleHumansMaleMiddle AgedAdenomaAdministration, OralTreatment Outcome

Stichwörter der Autor:innen

Bowel preparationColonoscopyOral mannitolPEG-ASC

Substanzen

CatharticsMannitolPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Pathophysiology and Organ Transplantation, University of Milan, Milan, Italy; IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy.
  • Divisione di Endoscopia, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • Department of Gastroenterology and Endoscopy, IRCCS Sacro Cuore Don Calabria, Negrar, Verona, Italy.
  • Ospedale Papa Giovanni XXIII, Bergamo, Italy.
  • UO Endoscopia Digestiva, Fondazione Poliambulanza - Istituto Ospedaliero, Brescia, Italy.
  • Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; Centre for Endoscopic Research Therapeutics and Training, Università Cattolica S. Cuore, Rome, Italy.

Förderung

  • National Transportation Center, Morgan State University

Zitieren

APA

Vecchi, M., Tontini, G. E., Fiori, G., Bocus, P., Carnovali, M., Cesaro, P., Costamagna, G., Paolo, D. D., Elli, L., Fedorishina, O., Hinkel, C., Jakobs, R., Kashin, S., Magnoli, M., Manes, G., Melnikova, E., Orsatti, A., Ponchon, T., Prada, A., …, & SATISFACTION Study Group (2025). Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial. Digestive and Liver Disease, 57(2), 574-583. https://doi.org/10.1016/j.dld.2024.09.024

Vancouver

Vecchi M, Tontini GE, Fiori G, Bocus P, Carnovali M, Cesaro P, et al. Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial. Digestive and Liver Disease. 2025;57(2):574-583. doi:10.1016/j.dld.2024.09.024

BibTeX
@article{Vecchi2025,
  author = {Vecchi, Maurizio and Tontini, Gian Eugenio and Fiori, Giancarla and Bocus, Paolo and Carnovali, Marino and Cesaro, Paola and Costamagna, Guido and Paolo, Dhanai Di and Elli, Luca and Fedorishina, Olga and Hinkel, Carsten and Jakobs, Ralf and Kashin, Sergey and Magnoli, Michela and Manes, Gianpiero and Melnikova, Ekaterina and Orsatti, Anna and Ponchon, Thierry and Prada, Alberto and Radaelli, Franco and Sferrazza, Sandro and Soru, Pietro and Valats, Jean Christophe and Veselov, Victor and Spada, Cristiano and Uebel, Peter and SATISFACTION Study Group, SATISFACTION Study Group},
  title = {Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial},
  journal = {Digestive and Liver Disease},
  year = {2025},
  volume = {57},
  number = {2},
  pages = {574--583},
  doi = {10.1016/j.dld.2024.09.024}
}
Kostenlos starten →